The Role of Lung-Resident Memory Th2 cells in Asthma
肺驻留记忆 Th2 细胞在哮喘中的作用
基本信息
- 批准号:9431929
- 负责人:
- 金额:$ 17.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-12-08 至 2022-12-06
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAdvisory CommitteesAllergensAllergic inflammationAnatomyAntigen PresentationAntigen-Presenting CellsAntigensAreaAsthmaAutomobile DrivingAwardBioinformaticsBiologyBloodCCL17 geneCCL22 geneCardiovascular systemCell physiologyCellsCellular biologyChronicConfocal MicroscopyCorrelative StudyDataDendritic CellsDevelopment PlansDiseaseEnvironmentEosinophiliaExhibitsExtrinsic asthmaFlow CytometryFoundationsFundingGeneral HospitalsGenetic TranscriptionGoalsHumanImmuneImmunityImmunologicsImmunologyInflammationInflammatoryInhalationInterdisciplinary StudyInvestigationLabelLigandsLungLung diseasesMassachusettsMediatingMemoryMentorsMentorshipMicroscopyModelingMucous MembraneMusOperative Surgical ProceduresParabiosisPhasePhenotypePopulationPositioning AttributeProductionPropertyPyroglyphidaeRecurrenceReporterReportingResearchResearch PersonnelRespiratory physiologyRoleSiteSystemT memory cellT-LymphocyteTechniquesTestingTh2 CellsTherapeuticTissuesTrainingTransgenic MiceTranslational ResearchWorkairborne allergenallergic airway inflammationcareer developmentchemokinecytokinein vivoinnovationinsightmouse modelnovelpathogenrecruitresponsesingle-cell RNA sequencingtranscriptome
项目摘要
Project Summary
Defining how memory T helper type 2 (Th2) cells initiate a recall response to an aeroallergen has the potential
to change our therapeutic approach to allergic asthma, the most common asthma subtype. During periods of
disease quiescence, approximately 5-10% of effector Th2 cells driving allergic asthma give rise to long-lived
memory cells that are poised to respond upon allergen re-exposure. Consequently, targeting memory Th2 cell
activation is an attractive therapeutic strategy. However, it is not well understood how allergen inhalation
initiates a memory Th2 cell response. Recently, a new paradigm in memory T cell biology has emerged in
which tissue-resident memory T cells (Trm) persisting in non-lymphoid tissue rapidly initiate recall responses.
While tissue-resident memory Th2 cells (Th2-Trm) have been described, the function of this population in
promoting allergic inflammation is unclear. The objective of this proposal is to define the mechanisms whereby
Th2-Trm persisting in the lung orchestrate a recall response to an inhaled allergen. Our central hypothesis is
that Th2-Trm ignite allergic airway inflammation via a rapid and enhanced response to cognate antigen and the
ability to recruit circulating Th2 cells to the sites of antigen presentation. Mechanistically, we hypothesize that
Th2-Trm co-localize with dendritic cells (DCs) expressing the Th2 cell-attracting chemokine CCL17 and after
allergen re-challenge rapidly produce type 2 cytokines that initiate allergic inflammation and markedly induce
DC expression of CCL17. This enhanced CCL17 expression recruits circulating Th2 cells from the blood to
sites of antigen presentation where they are activated, amplifying allergic inflammation. We propose to use
innovative experimental systems to define the function of Th2-Trm, including parabiosis of allergen-treated and
naïve mice, a novel CCL17/CCL22 reporter mouse as well as single cell RNA-seq analysis of airway mucosal
T cells from humans with allergic asthma. Specifically, we propose (1) To define the function of Th2-Trm in
regulating recurrent allergic airway inflammation and (2) To define the role of CCL17 in regulating Th2-Trm
localization and function. Dr. Rahimi will perform the work in this K08 proposal in the Center for Immunology
and Inflammatory diseases (CIID) at Massachusetts General Hospital (MGH) under the mentorship of Dr.
Andrew Luster. The CIID is a state-of-the-art multidisciplinary research center focused on mechanisms of
immune-mediated inflammatory diseases and is the foundation for immunology research at MGH. Dr. Rahimi
has developed a career development plan consisting of coursework in advanced microscopy, bioinformatics
and human translational research as well as organized a Training Advisory Committee to provide expertise and
assistance in these areas. The goal of this K08 award is to provide Dr. Rahimi with the intellectual and
technical training to become an independent, R01-funded investigator with expertise in the immunologic
mechanisms driving allergic asthma and other chronic eosinophilic lung diseases.
项目摘要
确定记忆性辅助性T细胞2型(Th 2)细胞如何启动对空气过敏原的回忆反应,
改变我们对过敏性哮喘的治疗方法,过敏性哮喘是最常见的哮喘亚型。时期
在疾病静止期,大约5-10%的效应Th 2细胞驱动过敏性哮喘引起长寿命的
记忆细胞准备对过敏原再次暴露做出反应。因此,靶向记忆Th 2细胞
活化是一种有吸引力的治疗策略。然而,目前还不清楚过敏原吸入是如何
启动记忆Th 2细胞应答。最近,在记忆T细胞生物学中出现了一种新的范式,
这种组织驻留记忆T细胞(Trm)持续存在于非淋巴组织中,迅速启动回忆反应。
虽然已经描述了组织驻留记忆性Th 2细胞(Th 2-Trm),但是该群体在免疫应答中的功能还不清楚。
促进过敏性炎症的原因尚不清楚。这项建议的目的是确定机制,
持续存在于肺中的Th 2-Trm协调对吸入性过敏原的回忆反应。我们的核心假设是
Th 2-Trm通过对同源抗原快速和增强的应答引发过敏性气道炎症,
将循环Th 2细胞募集到抗原呈递位点的能力。从机制上讲,我们假设
Th 2-Trm与表达Th 2细胞吸引趋化因子CCL 17的树突状细胞(DC)共定位,
过敏原再激发迅速产生2型细胞因子,其引发过敏性炎症并显著诱导
CCL 17的DC表达。这种增强的CCL 17表达从血液中募集循环Th 2细胞,
抗原呈递位点,在那里它们被激活,放大过敏性炎症。我们建议使用
创新的实验系统来定义Th 2-Trm的功能,包括过敏原处理的
未处理小鼠、新型CCL 17/CCL 22报告小鼠以及气道粘膜的单细胞RNA-seq分析
来自过敏性哮喘患者的T细胞。具体而言,我们建议(1)定义Th 2-Trm在
研究CCL 17在调节Th 2-Trm中的作用
定位和功能。Rahimi博士将在免疫学中心执行本K 08提案中的工作
和炎症性疾病(CIID)在马萨诸塞州总医院(MGH)的指导下,博士。
安德鲁·卢斯特CIID是一个最先进的多学科研究中心,专注于
免疫介导的炎症性疾病,是MGH免疫学研究的基础。Rahimi博士
制定了职业发展计划,包括高级显微镜、生物信息学等课程
和人类转化研究,并组织了一个培训咨询委员会,提供专业知识,
在这些领域的援助。这个K 08奖项的目标是为拉希米博士提供知识和
技术培训,成为一个独立的,R 01资助的研究者,具有免疫学专业知识,
导致过敏性哮喘和其他慢性嗜酸性肺病的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rod Amir Rahimi其他文献
Rod Amir Rahimi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rod Amir Rahimi', 18)}}的其他基金
Defining the development of tissue-resident memory Th2 cells in allergic asthma
定义过敏性哮喘中组织驻留记忆 Th2 细胞的发育
- 批准号:
10501568 - 财政年份:2022
- 资助金额:
$ 17.32万 - 项目类别:
Lipid shuttling in memory Th2 cell fate and function in allergic asthma
记忆中的脂质穿梭 过敏性哮喘中 Th2 细胞的命运和功能
- 批准号:
10572303 - 财政年份:2022
- 资助金额:
$ 17.32万 - 项目类别:
Defining the development of tissue-resident memory Th2 cells in allergic asthma
定义过敏性哮喘中组织驻留记忆 Th2 细胞的发育
- 批准号:
10670871 - 财政年份:2022
- 资助金额:
$ 17.32万 - 项目类别:
The Role of Lung-Resident Memory Th2 cells in Asthma
肺驻留记忆 Th2 细胞在哮喘中的作用
- 批准号:
10310428 - 财政年份:2017
- 资助金额:
$ 17.32万 - 项目类别:
The Role of Lung-Resident Memory Th2 cells in Asthma
肺驻留记忆 Th2 细胞在哮喘中的作用
- 批准号:
10065010 - 财政年份:2017
- 资助金额:
$ 17.32万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 17.32万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 17.32万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 17.32万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 17.32万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 17.32万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 17.32万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 17.32万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 17.32万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 17.32万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 17.32万 - 项目类别:














{{item.name}}会员




